Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2023-06-05 Share Issue/Capital Cha…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 May 2023
Share Issue/Capital Change Classification · 95% confidence The document is a monthly return report detailing movements in securities, specifically authorized and issued shares, for Overseas Chinese Town (Asia) Holdings Limited. It includes confirmations related to share capital and securities issuance under the Exchange Listing Rules of the Hong Kong Stock Exchange. The document is structured as a regulatory submission with no financial statements or management discussion. It is not an annual or interim report, earnings release, or any form of shareholder meeting material. It primarily reports on share capital and securities movements, which aligns with announcements about share capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length (6218 characters) and content confirm it is a substantive report rather than a brief announcement or certification, supporting this classification.
2023-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities, specifically focusing on authorized and issued share capital, share options, convertibles, and other share-related movements for RemeGen Co., Ltd. It includes confirmations related to share issuance and compliance with listing rules. The document is submitted to the Hong Kong Exchanges and Clearing Limited and is titled as a 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities.' This type of document is a regulatory filing that reports on share capital and share issuance activities but is not an announcement of a new share issue or capital change per se, nor is it a proxy, dividend, or management report. It is not a full financial report or earnings release. The content fits best under Regulatory Filings (RNS) as it is a compliance and disclosure document related to share capital movements and confirmations required by the exchange rules.
2023-06-01 English
PROXY FORM FOR ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is a proxy form for the Annual General Meeting (AGM) of Overseas Chinese Town (Asia) Holdings Limited. It includes instructions for shareholders to appoint proxies to vote on resolutions at the AGM, including receiving and considering the audited accounts, re-appointing auditors, re-electing directors, and approving amendments to the memorandum and articles of association. The document is not the AGM presentation or materials themselves but a form related to the AGM process. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms and voting materials.
2023-05-23 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a notice of the Annual General Meeting (AGM) for Overseas Chinese Town (Asia) Holdings Limited. It includes details about the date, time, venue, agenda items such as receiving audited accounts, re-appointment of auditors, re-election of directors, share allotment and repurchase mandates, and amendments to the memorandum and articles of association. The document is clearly a meeting notice rather than the actual annual report or financial statements. It is a formal announcement to shareholders about the AGM and the resolutions to be considered. Therefore, it fits the category of AGM Information (AGM-R). The document length and content confirm it is not a brief announcement or proxy solicitation but a full AGM notice.
2023-05-23 English
RENEWAL OF GENERAL MANDATES TO ISSUE NEW SHARES AND REPURCHASE SHARES PROPOSED RE-ELECTION OF DIRECTORS AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF T
AGM Information Classification · 95% confidence The document is a circular from Overseas Chinese Town (Asia) Holdings Limited related to the Annual General Meeting (AGM) scheduled for 20 June 2023. It includes information about the renewal of general mandates to issue and repurchase shares, proposed re-election of directors, proposed amendments to the memorandum and articles of association, and the notice of the AGM itself. The document contains the AGM notice, proxy form instructions, biographies of directors proposed for re-election, and explanatory statements related to the AGM resolutions. It is not a financial report, earnings release, or audit report, but rather materials and information provided to shareholders in connection with the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length (15,000 characters) and detailed content confirm it is the actual circular and not just an announcement of the AGM or a proxy solicitation. Hence, the classification is AGM-R with high confidence.
2023-05-23 English
VOLUNTARY ANNOUNCEMENT - RC198 RECEIVED ETHICS APPROVAL FOR THE PHASE I CLINICAL TRIAL IN AUSTRALIA, AND THE COMPANY WILL INITIATE THE STUDY TO TREAT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR MET
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding the receipt of ethics approval for a Phase I clinical trial in Australia and the initiation of the study. It contains no financial data, no regulatory filing references, no voting results, no management changes, no earnings or financial results, and no detailed report content. The document is relatively short (3185 characters) and serves as an announcement of a clinical trial milestone rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a voluntary announcement about a clinical trial progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-05-08 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.